Homepage Equant newsroom

Resmed expands contract with Equant to include IP Telephony

Announcement posted by Equant 20 Aug 2003

IP Telephony deal follows long-term frame relay contract and more recent equipment and Infrastructure maintenance contracts
Equant (NYSE: ENT) (Euronext Paris: EQU), an industry leader in global data and IP services for multinational businesses, has signed an agreement with ResMed, a leading global respiratory medical device company, to provide IP Telephony equipment, as well as design, installation and maintenance services.

ResMed is one of Equant Australias longest-standing customers. Its corporate data has run over frame relay for more than six years. ResMed is currently using Equant Frame Relay with Equant LAN Access, Equants fully managed VPN, which comprises both managed wide area connections and managed routers on the customer premises. Recently, Equant added global deployment and maintenance support of Cisco and Packeteer equipment to the services it provides to ResMed.

Building on the solid relationship between the two companies, ResMed has chosen Equant IP Telephony to upgrade its voice requirements.

We are always on the lookout for technology to help prepare the company for the future, and we believe that moving to IP Telephony will help us do that, said Shane Finn, global director of Information Technology at ResMed. We already had a well-established relationship with Equant and felt that they best understood our needs as we take our first step into this new area.

ResMed will be moving to a new purpose-built facility in Sydneys NorWest Business Park in 2004 to better support its constant growth. Equant will deploy IP Telephony equipment for ResMed, which will be used and managed at the new premises by ResMed as a key part of its voice and data infrastructure upgrade. Equant and ResMed have also discussed the possibility of Equant providing global IP telephony and converged voice and data networking to connect ResMeds offices across Australia, the United States, Europe and Asia in future stages.

In our evaluation of new technologies such as IP telephony, we were careful to select a global service provider that could meet our needs around the world, Finn said. We know that Equant will give us the same service and support no matter where we are, and that is often not the case with many smaller providers.

This deployment was initially on trial by approximately 80 users at ResMeds current North Ryde site, and will grow to 180 users at the new NorWest facility. When fully populated, several thousand staff will have access to IP Telephony. The roll-out involves a number of stages, ranging from basic telephony services, to voicemail, music on hold, conferencing, roaming phones, hot desking and integration with the companys legacy PABX and existing users.

Richard Knott, managing director, Equant Australasia said: ResMed understands the importance of communications as a business-critical function. They realize the benefits IP telephony and convergence can bring to their future business operations in terms of scalable, cost-effective and secure communications.

Our long-standing relationship with ResMed demonstrates the resilience and reliability of Equants global network solutions, as well as Equants ability to grow and mature with its customers as their voice and data requirements change, Knott said.

Equants existing contracts for frame relay and global maintenance on Cisco, Packeteer solutions and infrastructure services will remain intact with ResMeds move to its new facility. Equant Frame Relay is available in more than 740 cities in 148 countries and provides full management of all network facilities, network management and monitoring around the clock through five Global Customer Service Centers.

Plans are also in place to integrate the IP telephony solution at the new facility with ResMeds existing traditional telephony infrastructure at its old premises. This will ensure that the changeover keeps pace with the companys needs during the transition between sites.

Weve been watching the progress of IP telephony for approximately two years and decided that its now robust and scalable enough to meet our demands, said Finn. The new campus in Baulkham Hills will have capacity for several thousand people, all with IP telephony capability.

With Equant we are establishing and testing the platform and technologies that are needed to achieve our ultimate aim of having IP telephony and converged voice and data around the world, said Finn.

About Equant

Equant (NYSE: ENT) (Euronext Paris: EQU) is a recognized industry leader in global data and IP network and integration services for multinational businesses. The Equant network has unmatched seamless reach, connecting key business centers in 220 countries and territories, with local support in more than 165 countries. Building on more than 50 years of experience in data communications, Equant serves thousands of the worlds top companies with the industrys most extensive portfolio of managed network services, including the market-leading IP VPN used by 800 global businesses as of May 13, 2003. Equant, a member of the France Telecom Group, was named Best Global Carrier 2002 at the World Communication Awards and consistently leads industry surveys in corporate user satisfaction.

About ResMed

ResMed, headquartered in San Diego, Calif., is a leading developer, manufacturer, and marketer of medical equipment for the diagnosis, treatment and management of sleep-disordered breathing, selling a comprehensive range of products in more than 60 countries. ResMed is dedicated to improving the awareness among patients and healthcare professionals of the potentially serious health consequences of untreated SDB and to developing innovative technology to improve the lives of those who suffer from this condition. One key area of focus for ResMed is the link between SDB and life-threatening conditions including hypertension, stroke, and heart disease. For more information about ResMed, visit www.resmed.com or contact Walter Flicker at (858) 746-2211.

###

This release may contain projections or other forward-looking statements related to Equant that involve risks and uncertainties. Readers are cautioned that these statements are only predictions and may differ materially from actual future results or events. Readers are referred to the documents filed by Equant with the SEC, specifically the most recent filing on SEC Form 20-F, which identify important risk factors that could cause actual results to differ from those contained in the forward-looking statements, including, among other things, risks relating to Equants history of operating losses, the unpredictability of growth in Equants markets, Equants rapid growth, changing technology, uncertain and changing regulatory restrictions, Equants international operations, dependence on suppliers, network security issues, competition, and volatility of Equants stock price and risks relating to the combination with Global One. All forward-looking statements are based on information available to Equant